Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 1 of 4 (25%) have an AI response strategy ready • 4 patents granted in the last 365 days
Scholar Rock Inc. has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 2 distinct art units. This distribution indicates that the company is pursuing multiple patent applications simultaneously, with each of the 4 pending office actions being reviewed by a different individual. This variety of examiners suggests that the company must manage several different examination styles within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the portfolio is FAUST, AMBER KATHLEEN, who is currently handling 1 busiest examiner pending action. Because each of the 4 distinct examiners is managing exactly one action, the workload is evenly spread across the 2 distinct art units. This structure requires a broad prosecution strategy that addresses the specific concerns of FAUST, AMBER KATHLEEN and the other three examiners to resolve the 4 pending office actions effectively and advance the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283904 | TGF-BETA INHIBITORS AND USE THEREOF | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578341 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18363435 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF | SULLIVAN, DENNIS JOHN | — |
| 18250489 | USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578341 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | FAUST, AMBER KATHLEEN | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18283904 | TGF-BETA INHIBITORS AND USE THEREOF | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18363435 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF | SULLIVAN, DENNIS JOHN | 1642 | §112 | Non-Final OA | — | AI Ready | Aug 01, 2023 |
| 18250489 | USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Apr 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial